Inside the research

Becton, Dickinson and Company

BDX Research profile · latest available data

Price overview

$183.82

▲ +4.59 (+2.6%)

52w hi$190.87
52w lo$135.29
Vol1.47M
As of25 Sep 2026

The Verdict

Hold

Our score +0.22

Short+0.27
Medium+0.31
Long-0.06

computed 2026-09-27

Key fundamentals

Becton, Dickinson and Company

Healthcare · Medical Instruments & Supplies

Market cap$50.07B
Enterprise value$66.17B
Trailing P/E31.86x
Forward P/E13.83x
EV / EBITDA10.81x
P / S (ttm)2.23x
Profit margin4.2%
Return on equity6.6%
Revenue growth+5.4%
Earnings growth-31.4%
Debt / equity68.84

Layer Breakdown

LayerRawContribution
Fundamental+0.08
Sector+0.08
Technical+0.19
Earnings+0.00
Sentiment+0.00

macro × 1.00 · 2026-09-27

Business overview

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. It operates through Medical Essentials, Connected Care, BioPharma Systems, Interventional and Life Sciences segments. It provides peripheral intravenous (IV) and advanced peripheral catheters, central lines, acute dialysis catheters, vascular access technology, vascular care and preparation products, needle-free IV connectors and extensions sets, closed-system drug transfer devices, hazardous drug detections, hypodermic syringes and needles, anesthesia needles and trays, enteral syringes, and sharps disposal systems; IV medication safety and infusion therapy delivery systems, medication compounding workflow system, automated medication dispensing and supply management systems, informatics and analytics and pharmacy automation system, and medication inventory optimization and tracking system; hemodynamic monitoring system; and prefillable drug delivery systems. It also offers specimen and blood collection products; automated blood and tuberculosis culturing, molecular testing, and microorganism identification and drug susceptibility, as well as rapid diagnostic assays, microbiology laboratory automation products, and plated media products; and fluorescence-activated cell sorters and analyzers, antibodies and kits, reagent system, and solution for single-cell gene expression analysis, as well as clinical oncology, immunological, and transplantation diagnostic/monitoring reagents and analyzers. It provides hernia and soft tissue repair, biological and bioresorbable graft, biosurgery, and other surgical products; surgical infection prevention, peripheral intervention, and urology and critical care products. The company has a strategic collaboration with ChemoGLO for the advancement of hazardous drug contamination testing in health care settings to improve the safety of health care workers. The company was founded in 1897 and is headquartered in Franklin Lakes, New Jersey.

United States · www.bd.com

Risk Metrics

Beta vs SPX0.46
Corr SPX0.27
Annual vol28.0%
Annual ret+4.1%
Sharpe0.15
Max DD-33.7%

Window: 504 trading days (504 obs)

Analyst Coverage

Mean PT$183.29
High / Low$225.00 / $156.00
Median$176.00
Analysts14
Strong Buy1
Buy6
Hold9
Sell0
Strong Sell0

Recent rating actions

2026-05-08Wells Fargo→ Equal-Weight
2026-05-04TD Cowen→ Hold
2026-04-17Piper Sandler→ Neutral
2026-03-23Argus Research→ Buy
2026-02-11Citigroup→ Buy
2026-02-10Wells Fargo→ Equal-Weight

Material Events

DateEvent8-K
2026-08-06Earnings Release, Exhibitsread
2026-07-22Officer / Director Change, Reg FD Disclosure…read
2026-05-29Reg FD Disclosureread
2026-05-20Material Agreement, Material Obligation…read
2026-05-12Other Material Event, Exhibitsread
2026-05-07Earnings Release, Exhibitsread
2026-04-29Bylaws Amendment, Exhibitsread
2026-04-09Officer / Director Change, Reg FD Disclosure…read
2026-04-02Earnings Release, Exhibitsread
2026-02-25Other Material Event, Exhibitsread
2026-02-10Other Material Event, Exhibitsread
2026-02-09Material Agreement, Officer / Director Change…read

Connections

Subsidiarys: BD Interventional

Dividends

Yield (TTM)1.02%
$ / share (TTM)$1.88
5y CAGR+6.0%

Annual dividend per share

2021$2.58
2022$2.75
2023$2.89
2024$3.06
2025$3.28
2026$1.05

Federal Contracts

AmountAgencyDescription
$74.94MDepartment of Veterans AffairsCOVID-19 TEST KITS
$33.79MDepartment of Health and Human ServicesBECTON DICKENSON: MULTIPLEXED RESPIRATORY PANEL TESTS FOR THE BD VERITOR, THE BD
$4.08MDepartment of Health and Human ServicesFACSYMPHONY A5 SE CELL ANALYZERS (8 CELL ANALYZERS)
$2.18MDepartment of Veterans AffairsBD REAGENTS AND SUPPLIES
$1.99MDepartment of Health and Human ServicesPURCHASE ORDER - BASE PERIOD - MAINTENANCE SERVICE CONTRACT FOR VARIOUS GOVERNME
$1.94MDepartment of Veterans AffairsFLOW CYTOMETRY
$1.42MDepartment of DefenseA5SE BD FACSYMPHONY CELL ANALYZER
$1.27MDepartment of Veterans AffairsCTX MICROBIOLOGY AUTOMATION SYSTEM

SEC Filings

DateFormDoc
2026-08-144view
2026-08-124view
2026-08-0610-Qview
2026-08-068-Kview
2026-08-064view
2026-08-064view
2026-07-284view
2026-07-228-Kview
2026-07-064view
2026-06-2911-Kview
2026-06-2911-Kview
2026-06-264view
2026-06-254view
2026-06-223view
2026-06-114view

The Long Run

FY 2009–2025 · 17 years

LineLatestCAGRTrend
Revenue$21.84B+7.2%
Gross profit$1.66B+9.7%
Operating income$2.40B+2.8%
Net income$1.68B+5.4%
Cash from ops$3.33B+5.4%

Indices

S&P 500

Recent Sessions

DateOpenHighLowCloseVol
Sep 25$179.22$183.92$177.87$183.821.47M
Sep 24$182.73$183.72$178.98$179.231.40M
Sep 23$182.10$184.37$181.31$182.521.02M
Sep 22$182.40$183.83$180.75$183.001.46M
Sep 21$181.25$181.53$179.98$180.701.46M

Understand the score. Research layers are inputs to a model, and the available data has limits.

Read the methodology →